Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$40.45 USD

40.45
2,749,117

+0.01 (0.02%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $40.51 +0.06 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why Exelixis (EXEL) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

by Zacks Equity Research

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Is First Trust Mid Cap Core AlphaDEX ETF (FNX) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FNX

Zacks Equity Research

Should First Trust Mid Cap Core AlphaDEX ETF (FNX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FNX

Zacks Equity Research

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JHSC

Zacks Equity Research

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Is John Hancock Multifactor Small Cap ETF (JHSC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JHSC

Ekta Bagri headshot

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

by Ekta Bagri

CORT and AXSM are in the spotlight this week following the announcement of study data.

Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of 0% and 67.85%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

by Zacks Equity Research

Exelixis obtains FDA nod for label expansion of lead drug Cabometyx for neuroendocrine tumors.

Zacks Equity Research

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

by Zacks Equity Research

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders.

Zacks Equity Research

Here's Why Exelixis (EXEL) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

by Zacks Equity Research

Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors have been highlighted in this Screen of The Week article.

Urmimala Biswas headshot

4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty

by Urmimala Biswas

Here are four PEG-based GARP picks, GILD, EXEL, SYF and TAP, which qualify our screening criteria.

Zacks Equity Research

EXEL or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.